StreetInsider.com News Articles

Integra LifeSciences closes $450M notes offering and refinances debt

Mon, 19 Oct 2026 16:32:19 -0400

Integra LifeSciences Holdings Corporation (NASDAQ: IART) has completed a private offering of $450 million in aggregate principal amount of 9.500% senior secured notes due 2033, according to a press release from the Princeton, N.J.-based company.

Integra also amended and restated its existing credit facility, bringing the total size to approximately $1.65 billion. The restructured credit facility consists of a $600 million senior secured revolving credit facility with a five-year maturity, a $600 million senior secured term loan A facility with a five-year maturity, and a $450 million senior secured term loan B facility with a seven-year maturity.

The notes are general senior

Form 8-K INTEGRA LIFESCIENCES For: Oct 19

Mon, 19 Oct 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20261019/27204147.html

Integra Announces Completion of Refinancing Transactions

Mon, 19 Oct 2026 16:05:00 -0400

PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it has closed a private offering of $450.0 million aggregate principal amount of 9.500% senior secured notes due 2033 (the “Notes”). In addition, Integra announced today that it has amended and restated its existing credit facility, with an overall size of approximately $1.65 billion consisting of (i) a $600 million senior secured revolving credit facility with a five year maturity, (ii) a $600 million senior secured term loan A facility with a five year maturity and (iii) a $450 million senior

Integra Announces Completion of Refinancing Transactions

Mon, 19 Oct 2026 16:05:00 -0400

Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting

Fri, 16 Oct 2026 08:39:00 -0400

PRINCETON, N.J., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO, taking place October 17-20 in Los Angeles, California.

At this year's meeting, Integra will showcase its growing portfolio of ENT technologies and instruments, including the ACCLARENT AERA® Eustachian Tube Treatment, TruDi® Navigation System, MicroFrance® ENT and Laparoscopy Instruments, Bien-Air® Drill and Shaver Systems and RELIEVA SPINPLUS® Balloon Sinuplasty System.

Additionally, Integra is a sponsor of

Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting

Fri, 16 Oct 2026 08:39:00 -0400

Additionally, Integra is a sponsor of

Integra LifeSciences (IART) PT Lowered to $15 at Truist Securities

Wed, 14 Oct 2026 07:00:09 -0400

Truist Securities analyst Richard Newitter lowered the price target on Integra LifeSciences (NASDAQ: IART) to $15.00 (from $19.00) while maintaining a Hold rating.

Form 3 INTEGRA LIFESCIENCES For: Oct 01 Filed by: Caruso Andrea B

Tue, 13 Oct 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20261013/27181888.html

Form 8-K INTEGRA LIFESCIENCES For: Oct 09

Fri, 09 Oct 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20261009/27172385.html

Integra LifeSciences prices $450M in senior secured notes

Fri, 09 Oct 2026 17:22:29 -0400

Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced the pricing of $450 million in aggregate principal of 9.500% senior secured notes due 2033, according to a press release from the Princeton, N.J.-based company.

The notes will serve as general senior secured obligations of the company, guaranteed by its wholly-owned domestic subsidiaries that are guarantors under its existing senior secured credit facilities. The sale is expected to close on or about October 19, 2026, subject to customary closing conditions.

The company intends to use the net proceeds, together with borrowings under new credit facilities, to refinance its existing credit facilities and cover related fees

Integra Announces Pricing of Senior Secured Notes

Fri, 09 Oct 2026 17:22:00 -0400

PRINCETON, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) (the “Company”) today announced the pricing of $450,000,000 aggregate principal amount of 9.500% senior secured notes due 2033 (the “Notes”). The Notes will be general senior secured obligations of the Company and will be guaranteed by the Company’s wholly-owned domestic subsidiaries that are guarantors under the Company’s senior secured credit facilities. The sale of the Notes is expected to close on or about October 19, 2026, subject to customary closing conditions.

The Company intends to use the net proceeds from the offering of Notes,

Integra Announces Pricing of Senior Secured Notes

Fri, 09 Oct 2026 17:22:00 -0400

The Company intends to use the net proceeds from the offering of Notes,

Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026

Tue, 06 Oct 2026 08:30:00 -0400

PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2026 financial results on Wednesday, October 21, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.

A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required,

Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026

Tue, 06 Oct 2026 08:30:00 -0400

Integra LifeSciences (IART) PT Lowered to $15 at BMO Capital

Mon, 05 Oct 2026 09:11:03 -0400

(Updated - October 5, 2026 9:11 AM EDT)

BMO Capital analyst Vik Chopra lowered the price target on Integra LifeSciences (NASDAQ: IART) to $15.00 (from $18.00) while maintaining a Market Perform rating.

The analyst commented: "Updating Estimates for Preliminary Results; Integra LifeSciences pre-announced preliminary Q3 2026 results and cut full-year guidance, citing greater-than-expected disruption from the July flooding at its Cincinnati facility (part of the Specialty Surgical Technologies portfolio). New FY26 guidance sits below our and Street estimates on both revenue and EPS. As a result, we are lowering our estimates."

Integra LifeSciences (IART) PT Lowered to $15 at BMO Capital

Mon, 05 Oct 2026 09:11:03 -0400

(Updated - October 5, 2026 9:11 AM EDT)

BMO Capital analyst Vik Chopra lowered the price target on Integra LifeSciences (NASDAQ: IART) to $15.00 (from $18.00) while maintaining a Market Perform rating.

Integra LifeSciences (IART) PT Lowered to $15 at Wells Fargo

Mon, 05 Oct 2026 05:39:12 -0400

Wells Fargo analyst Larry Biegelsen lowered the price target on Integra LifeSciences (NASDAQ: IART) to $15.00 (from $18.00) while maintaining a Equal Weight rating.

The analyst comments "Updating our estimates. We are lowering our 2026 revenue estimate to $1.648B from $1.679B and our adjusted EPS estimate to $2.35 from $2.45 driven by lower Specialty Surgical related revenue. For 2027, we now model revenue of $1.701B down from $1.725B and adjusted EPS of $2.68 versus $2.71 as we assume insurance partially offsets IART's lower revenue. We lower our price target to $15 from $18 which is based on 5.5x (6.5x, prev.) our

Integra LifeSciences (IART) PT Lowered to $15 at Wells Fargo

Mon, 05 Oct 2026 05:39:12 -0400

Wells Fargo analyst Larry Biegelsen lowered the price target on Integra LifeSciences (NASDAQ: IART) to $15.00 (from $18.00) while maintaining a Equal Weight rating.

Integra LifeSciences stock tumbles after cutting 2026 outlook

Fri, 02 Oct 2026 10:12:50 -0400

Investing.com -- Integra LifeSciences Holdings (NASDAQ:IART) shares fell 14% in Friday trading after the company cut its full-year 2026 guidance due to ongoing impacts from flooding at its Cincinnati manufacturing facility.

The medical technology company reduced its 2026 revenue outlook to a range of $1.634 billion to $1.654 billion, down from the previous range of $1.654 billion to $1.695 billion. Adjusted earnings per diluted share guidance was lowered to $2.30 to $2.40 from $2.40 to $2.50. Wall Street had expected full-year revenue of $1.67 billion and earnings of $2.46 per share.

For the third quarter, Integra expects revenue of

Integra LifeSciences stock tumbles after cutting 2026 outlook

Fri, 02 Oct 2026 10:12:50 -0400

For the third quarter, Integra expects revenue of

Form 8-K INTEGRA LIFESCIENCES For: Oct 02

Fri, 02 Oct 2026 08:20:00 -0400

si-local-file:///var/storage/secattach/20261002/27139091.html

Integra LifeSciences cuts 2026 outlook after Cincinnati flood

Fri, 02 Oct 2026 08:06:08 -0400

Integra LifeSciences Holdings Corporation (Nasdaq: IART) lowered its full-year 2026 revenue and earnings guidance after flooding at its Cincinnati manufacturing facility disrupted production during the third quarter.

The company now expects full-year 2026 revenue of $1.634 billion to $1.654 billion, down from its prior outlook of $1.654 billion to $1.695 billion. Adjusted earnings per diluted share guidance was reduced to a range of $2.30 to $2.40, from a prior range of $2.40 to $2.50. The company maintained its operating cash flow forecast at approximately $190 million to $200 million for the full year.

For the third quarter of 2026, Integra expects to

Integra LifeSciences cuts 2026 outlook after Cincinnati flood

Fri, 02 Oct 2026 08:06:08 -0400

For the third quarter of 2026, Integra expects to

Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance

Fri, 02 Oct 2026 08:05:00 -0400

PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance.

“Our third quarter results were impacted by the July flooding event at our Cincinnati facility,” said Stuart Essig, Chairman and Chief Executive Officer. “Our teams have made significant progress executing recovery plans and supporting customers. As we have gained additional visibility into the recovery timeline and production ramp, we now have a clearer understanding of the expected impact on

Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance

Fri, 02 Oct 2026 08:05:00 -0400